



CSL Behring – Withdrawal of Hizentra® [immune globulin subcutaneous (human)]

- On January 10, 2022 [CSL Behring announced](#) an expansion to a patient-level withdrawal, to include two additional lots of [Hizentra \[immune globulin subcutaneous \(human\)\]](#) due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration. This is an expansion to the withdrawal that was announced on December 30, 2021.
- The withdrawn lots were shipped from CSL Behring between October 5, 2021 and December 15, 2021.

Product Description	NDC	Lot # (Expiration Date)
Hizentra [immune globulin subcutaneous (human)] 20% liquid	44206-0455-10	P100369102 (2/16/2024); P100369103 (2/18/2024)

- Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
- Injection-site reactions and hypersensitivity are a known risk with subcutaneous immune globulin products.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the withdrawn Hizentra.
- Contact CSL Behring Medical Information at **1-800-504-5434** or email **MedinfoNA@cslbehring.com** for more information about the withdrawal.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.